| Project/Area Number |
25460156
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Drug development chemistry
|
|---|
| Research Institution | Tokyo University of Science |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TAKASAWA Ryoko 東京理科大学, 薬学部・薬学科, 講師 (10398828)
藤川 誠 東京医科歯科大学, 医歯(薬)学総合研究科, 助教 (90573048)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 医薬分子設計 / 癌 / Met / チロシンキナーゼ阻害剤 / in silico分子設計 / ペプチド / アロステリック部位 / アポトーシス / チロシンキナーゼ / キナーゼ阻害剤 / in cilico分子設計 |
|---|
| Outline of Final Research Achievements |
The receptor-type tyrosine kinase Met, which is known to involved in the many steps of cancer growth and development, is an attractive molecular target for the creation of new anticancer drugs. In this study, we attempted to create new small molecular inhibitors through the most optimized-binding peptide as a design-chip, which is designed by using inactive form of Met. Interestingly, we could discover novel inhibitors, which bind to the allosteric site of Met molecule.
|
